Health Topics

Biomarker, tissue study shows body composition in patients treated with Ozempic
By Liz Carey
Artificial intelligence tools may aid healthcare teams in monitoring the negative impacts of weight loss and diabetes drugs.
September 20, 2024
30-year-old woman with semaglutide use. Patient had stopped semaglutide use 36 days prior to post-semaglutide scan. Patient's weight was 148 kg on pre-semaglutide scan and 176 kg on post-semaglutide scan. Patient was thus assigned to weight-gain group. (A) Coronal maximum-intensity projection (MIP) image from pre-semaglutide scan shows organ segmentations. (B) Axial image from pre-semaglutide scan at L3 level shows color-coded tissue segmentations. (C) Coronal MIP image from post-semaglutide scan shows organ segmentations. (D) Axial image from post-semaglutide scan at L3 level shows color-coded tissue segmentations. Segmented visceral adipose tissue (VAT) is colored yellow, subcutaneous adipose tissue (SAT) is colored blue, skeletal muscle is colored red, liver is colored red, and spleen (not evaluated in present investigation) is colored orange. On pre- and post-semaglutide scans, VAT area was 358.5 cm2 and 412.1 cm2, muscle area was 186.8 cm2 and 225.2 cm2, muscle attenuation was -5.2 HU and -11.0 HU, liver volume was 2,579 and 3,851 mL, and liver attenuation was 77.8 HU and 59.2 HU, respectively. Images and caption courtesy of the American Journal of Roentgenology.
Rapid diagnostic test developed for ALS
By LabPulse.com staff writers
A blood diagnostic test for amyotrophic lateral sclerosis (ALS) has been developed that can rapidly distinguish ALS from conditions that mimic ALS in its early stages with a high level of specificity and sensitivity.
September 13, 2024
Nerve Neuron Axon Social
C2N, Unilabs sign global agreement on early Alzheimer's diagnostics
By LabPulse.com staff writers
C2N and Unilabs have signed a multiyear agreement that will increase access to C2N's Precivity blood tests for the early diagnosis of Alzheimer's disease to Unilabs' testing network on an exclusive basis.
August 8, 2024
Alzheimers Phases Amyloid Social
Diagnostic laboratory joint venture expands RNA sequencing at Baylor
By LabPulse.com staff writers
WT RNAseq goes beyond the interpretation of already identified variants by whole exome sequencing (WES) or whole genome sequencing (WGS), according to Baylor Genetics.
August 6, 2024
Sequencing Dna Rna Social (1)
ALZpath, Roche sign licensing agreement for dementia biomarker
By LabPulse.com staff writers
ALZpath has signed a licensing agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize a diagnostic blood test for Alzheimer's disease that will be offered on the Roche Elecsys platform.
June 12, 2024
Amyloid Plaque Alzheimer2 Social
Study: Model predicts dementia years before clinical diagnosis
By LabPulse.com staff writers
Researchers have developed a model that predicts dementia up to nine years before a clinical diagnosis. With greater than 80% accuracy, the test is potentially more reliable than current methods in common use for diagnosis.
June 7, 2024
Amyloid Plaque Alzheimer Social
GeneDx launches exome sequencing access program for pediatric epilepsy patients
By LabPulse.com staff writers
Genetic testing firm GeneDx has launched a patient access program aimed at increasing access to exome sequencing for pediatric patients with epilepsy.
June 5, 2024
Dna Sequence Social
BioMérieux TBI test receives FDA 510(k) clearance
By LabPulse.com staff writers
BioMérieux has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its assay that screens for mild traumatic brain injury, including concussion.
May 29, 2024
Football Player Concussion Social
Nanopath awarded $4M in SBIR grants
By LabPulse.com staff writers
Nanopath has announced that it has been awarded two grants worth a total of $4 million in federal funding through the Small Business Innovation Research (SBIR) program.
May 22, 2024
Research Money Social
Backlog of unresolved medical diagnoses leads to new method for clinical exome reanalysis
By Liz Carey
The automated analysis improved the rate of accurate genetic diagnosis, doubling the number of solved cases as compared with benchmarked methods, across three distinct real-world cohorts, according to researchers.
May 16, 2024
Child Hospital Social
BioMarin confirms layoffs and R&D cuts
By LabPulse.com staff writers
Roctavian, BioMarin's gene therapy for severe hemophilia A, generated $800,000 in net product revenue in the first quarter of 2024.
May 15, 2024
Business Graph Money Stocks Social
Danaher launches collaboration with Johns Hopkins University on TBI diagnostics
By LabPulse.com staff writers
Danaher has launched a partnership with Johns Hopkins University aimed at developing new traumatic brain injury (TBI) diagnostics.
May 9, 2024
Artificial Intelligence Brain Close Social
Page 1 of 70
Next Page